Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Empagliflozin improves symptoms in diabetic neuropathy
Last updated September 9, 2026
Key finding
Haemoglobin A1c decreased significantly from baseline.
The study investigated the effects of empagliflozin on glycaemic control and neuropathic symptoms in patients with type 2 diabetes and peripheral neuropathy, showing significant improvements in several key outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the effects of empagliflozin on glycaemic control and neuropathic symptoms in patients with type 2 diabetes and peripheral neuropathy, showing significant improvements in several key outcomes.
Clinical relevance
These findings suggest that empagliflozin may be an effective treatment option for managing both blood sugar levels and neuropathic symptoms in individuals with type 2 diabetes. Improved glycaemic control can lead to better overall health outcomes and quality of life for patients suffering from diabetes-related complications.
Keep in mind
Unclear effectiveness for some outcomes Potential limitations in generalizability Sample size not specified
Published in
Journal Reference
Publication details and source links for this paper.
Mohammadreza V, Fatemeh MM, Amidodin K, Akram G, Marzieh ZB, Raihane A. Empagliflozin Improves Glycaemic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes and Peripheral Neuropathy. Endocrinology, Diabetes & Metabolism. 2025;8(6):e70128. doi:10.1002/edm2.70128
Main Effects
Haemoglobin A1c decreased by 0.21% (p=0.001)
Fasting plasma glucose decreased by 6.46 mg/dL (p=0.001)
Nerve conduction velocity improved significantly (p=0.001)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and Amplitude, Change in Michigan Neuropathy Screening Instrument score, Estimated glomerular filtration rate, and 5 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Amplitude
- Change in Michigan Neuropathy Screening Instrument score
- Estimated glomerular filtration rate
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
8
Evidence pairs
1510
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
SGLT2 Inhibitors and HbA1c
Related evidence
Evidence relationship
SGLT2 Inhibitors and Kidney Function
Save evidence
Evidence relationship
SGLT2 Inhibitors and Fasting Glucose
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Change in Michigan Neuropathy Screening Instrument score
Empagliflozin → Change in Michigan Neuropathy Screening Instrument score
Empagliflozin → Change in Michigan Neuropathy Screening Instrument score
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEstimated glomerular filtration rate
Empagliflozin → Estimated glomerular filtration rate
Empagliflozin → Estimated glomerular filtration rate
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Empagliflozin → Fasting Plasma Glucose (FPG)
Empagliflozin → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Trackermedian nerve conduction velocity (MNCV)
Empagliflozin → median nerve conduction velocity (MNCV)
Empagliflozin → median nerve conduction velocity (MNCV)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerReduction in Hemoglobin A1C levels
Empagliflozin → Reduction in Hemoglobin A1C levels
Empagliflozin → Reduction in Hemoglobin A1C levels
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Haemoglobin A1c decreased significantly by 0.21%
- Fasting plasma glucose decreased significantly by 6.46 mg/dL
- Nerve conduction velocity improved significantly
Who this applies to
- Adults with type 2 diabetes
- Patients experiencing peripheral neuropathy
Keep in Mind
- Results may not apply to all diabetes types
- Further studies needed to confirm findings
- Effectiveness unclear for some measured outcomes
Between the Lines
- Unclear effectiveness for some outcomes
- Potential limitations in generalizability
- Sample size not specified
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Fasting Glucose, SGLT2 Inhibitors and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 80
- Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
View evidenceMedications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
5 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
5 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
2 studies
outcome_hubMeasures HbA1c as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Empagliflozin and Fasting Plasma Glucose (FPG)
Intervention: EmpagliflozinOutcome: Fasting Plasma Glucose (FPG)
5 results
All studies on Empagliflozin and Reduction in Hemoglobin A1C levels
Intervention: EmpagliflozinOutcome: Reduction in Hemoglobin A1C levels
2 results
All studies on Empagliflozin
Intervention: Empagliflozin
5 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
5 results
All studies measuring Reduction in Hemoglobin A1C levels
Outcome: Reduction in Hemoglobin A1C levels
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do SGLT2 Inhibitors lower HbA1c?
Strong Evidence
SGLT2 Inhibitors may lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Reduction in Hemoglobin A1C levels
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 25 supporting studies with consistent results and a positive effect signal.
Do SGLT2 Inhibitors improve kidney function?
Strong Evidence
SGLT2 Inhibitors may improve kidney function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Estimated glomerular filtration rate
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Serum creatinine
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Do SGLT2 Inhibitors improve fasting glucose?
Strong Evidence
SGLT2 Inhibitors may improve fasting glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 83.1 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Does Empagliflozin improve latency?
Emerging Evidence
Empagliflozin appears to improve latency.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Latency
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Combination therapy improves liver health in type 2 diabetesEmpagliflozin does not change sympathetic activity in type 2 diabetesEmpagliflozin improves heart function in type 2 diabetes patientsEmpagliflozin improves glycemic control in type 2 diabetes patientsEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.